Pilot study on the use of psychotropic medication in persons with mental retardation

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 5, 2004, Pages 879-883

  Radouco Thomas, Monelly ^a,c   Bolduc, Michel ^a   Brisson, Anick ^a   Brassard, Pierre ^a   Fortier, Lucie ^a   Thivierge, Jacques ^a,b,c  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

AD; Antidepressive medication; Antipsychotics; AP; B; Benzodiazepines; Community residential facilities; CRF; D sample; Deinstitutionalization; In patient sample; In sample; M; Mental retardation; Psychotropic medications

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

AGE DISTRIBUTION; ARTICLE; DIAGNOSTIC VALUE; DISEASE SEVERITY; HUMAN; MENTAL DEFICIENCY; MENTAL HOSPITAL; PILOT STUDY; SEX DIFFERENCE; TREATMENT WITHDRAWAL;

ADULT; AGED; DEINSTITUTIONALIZATION; DRUG UTILIZATION; FEMALE; HUMANS; INPATIENTS; MALE; MENTAL RETARDATION; MIDDLE AGED; PILOT PROJECTS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES;

EID: 4444323268     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2004.05.029     Document Type: Article

References (31)

1. Ahmed Z., Fraser W., Kerr M.P., Kiernan C., Emerson E., Robertson J., Felce D., Allen D., Baxter H., Thomas J. Reducing antipsychotic medication in people with a learning disability. Br. J. Psychiatry. 176:2000;42-46
2. Aman M.G. Drugs and learning in mentally retarded persons. Burrows G.D., Werry J.S. Advances in Human Psychopharmacology. vol. 3:1984;121-163 JAI Press, Greenwich
3. Aman M.G., Sarphare G., Burrow W.H. Psychotropic drugs in group homes: prevalence and relation to demographic/psychiatric variables. Am. J. Ment. Retard. 99(5):1995;500-509
4. Barnes T.R.E., Braude W.M. Akathisia variants and tardive dyskinesia. Arch. Gen. Psychiatry. 42(Sept.):1985;874-878
5. Branford D. Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. JIDR, J. Intellect. Disabil. Res. 40(4):1996;322-329
6. Braude W.M., Barnes T.R.E., Gore S.M. Clinical characteristics of akathisia. Br. J. Psychiatry. 143:1983;139-150
7. Breuning S.E., Davis V., Matson J., Ferguson D. Effects of thioridazine and withdrawal dyskinesias on workshop performance of mentally retarded young adults. Am. J. Psychiatry. 139(11):1982;1447-1454
8. Briggs R. Monitoring and evaluation psychotropic drug use for persons with mental retardation: a follow-up report. Am. J. Ment. Retard. 93(6):1989;633-639
9. Chadsey-Rusch J., Sprague R.L. Maladaptive behaviours associated with neuroleptic drug maintenance. Am. J. Ment. Retard. 6:1989;607-617
10. Clarke D.J., Kelly S., Thinn K., Corbett J.A. Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. J. Ment. Defic. Res. 34:1990;385-395
11. Ellenor G.L., Frisk A. Pharmacist impact on drug use in an institution for the mentally retarded. Am. J. Hosp. Pharm. 34:1977;804-808
12. Gualtieri C.T., Schroeder S.R., Hicks R., Quade D. Tardive dyskinesia in young mentally retarded individuals. Arch. Gen. Psychiatry. 43:1986;335-340
13. Hemming H. Psychotropic medication needs of mentally retarded adults before and after transfer from large institutions to new small units. Perspectives and Progress in Mental Retardation. vol. II:1984;349-356. Biomedical Aspects Edi. JM Berg copyright 1984 by I.A.S.S.M.D.
14. Hill B.K., Balow E.A., Bruininks R.H. A national study of prescribed drugs in institutions and community residential facilities for mentally retarded people. Psychopharmacol. Bull. 21(2):1985;274-284
15. Howerton K., Fernandez G., Touchette P.E., Gurbani S., Sandman C.A., Ashurst J., Nahnovski N., Downing A., Lott I.T. Psychotropic medications in community based individuals with developmental disabilities: observations of an interdisciplinary team. Ment. Health Aspects Develop. Disab. 5(3):2002;78-86
16. Inoue F. A clinical pharmacy service to reduce psychotropic medication use in an institution for mentally handicapped persons. Ment. Retard. 20(2):1982;70-74
17. Intagliata J., Rinck C. Psychoactive drug use in public and community residential facilities or mentally retarded persons. Psychopharmacol. Bull. 21(2):1985;268-278
18. La Mendola W., Zaharia E.S., Carver M. Reducing psychotropic drug use in an institution for the retarded. Hosp. Community Psychiatry. 31(4):1980;271-272
19. Lee J.W.Y., Robertson S. Clozapine withdrawal catatonia and neuroleptic malignant syndrome: a case report. Ann. Clin. Psychiatry. 9(3):1997;165-169
20. Linaker O.M. Frequency of and determinants for psychotropic drug use in an institution for the mentally retarded. Br. J. Psychiatry. 156:1990;525-530
21. Lipman R.S. The use of pharmacological agents in residential facilities for the retarded: menolascino FJ. Psychiatric Approaches to Mental Retardation. 1970;387-398 Basic, NY
22. Luchins D.J., Dojka D.M., Hanrahan P. Factors associated with reduction in antipsychotic medication dosage in adults with mental retardation. Am. J. Ment. Retard. 98(1):1993;165-172
23. May P., London E.B., Zimmerman T., Thompson R., Mento T., Spreat S. A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Ann. Clin. Psychiatry. 7(4):1995;155-160
24. Mikkelsen E.J. Low-dose haloperidol for Stereotypic self-injurious behavior in the mentally retarded. N. Engl. J. Med. 315(6):1986;398-399
25. Rifkin Antipsychotic drugs in mentally retarded persons: a critical review. NADD Bull. 2(2):1999;127-130
26. Sprague R.L. Counting jars of raspberry jam. Anderson R.P., Halcomb C.G. Learning disability/minimal brain dysfunction syndrome. 1976;94-125 Charles C. Thomas, Springfield, IL
27. Sprague R.L. Litigation, legislation and regulations. Breuning S., Poling A. Drugs and Mental Retardation. 1982;377-414 Charles C. Thomas, Springfield, IL
28. Spreat S., Conroy J.W., Jones J.C. Use of psychotropic medication in Oklahoma: a statewide survey. Am. J. Ment. Retard. 102(1):1997;80-85
29. Thinn K., Clarke D.J., Corbett J.A. Psychotropic drugs and mental retardation: 2. A comparison of psychoactive drug use before and after discharge from hospital to community. J. Ment. Defic. Res. 34:1990;397-407
30. Thivierge J., Bolduc M., Cossette L., Radouco-Thomas M., Bellavance A., Brassard P. Persons with pervasive developmental disorders and their families. Can. Psychiatr. Assoc. Bull. 2001;64-65
31. Zimmermann R.L., Heistad G.T. Studies of the long term: efficacy of antipsychotic drugs in controlling the behavior of institutionalized retardates. J. Am. Acad. Child Psych. 21(2):1982;136-143